Latest Views & News

OptiBiotix Health – agreement with Firmenich, remains a Strong Buy

By Tom Winnifrith & Steve Moore | Wednesday 13 July 2022

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Writing on OptiBiotix Health (OPTI) last month with the shares at 21p to buy, we noted potential for a move into meaningful profitability and further potential from 'second generation' products addressing much larger market opportunities. We drank our own medicine with Tom buying more shares at 22p. The shares are now further up at 31.5p on the back of a “Joint development agreement signed with Firmenich”-titled announcement.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Tuesday »


Synectics – a recovery Buy?



Malcolm Stacey is Moving House

Monday »


Wood Group - a Buy (again)?



Video: Bubbles always implode